Annual Long Term Debt
$86.27 M
+$41.76 M+93.80%
December 31, 2024
Summary
- As of March 12, 2025, RXRX annual long term debt is $86.27 million, with the most recent change of +$41.76 million (+93.80%) on December 31, 2024.
- During the last 3 years, RXRX annual long term debt has risen by +$76.30 million (+765.14%).
- RXRX annual long term debt is now at all-time high.
Performance
RXRX Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Debt
$86.27 M
+$12.10 M+16.31%
December 31, 2024
Summary
- As of March 12, 2025, RXRX quarterly long term debt is $86.27 million, with the most recent change of +$12.10 million (+16.31%) on December 31, 2024.
- Over the past year, RXRX quarterly long term debt has increased by +$12.10 million (+16.31%).
- RXRX quarterly long term debt is now at all-time high.
Performance
RXRX Quarterly Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Debt Formula
Long-Term Debt = Bonds Payable + Long-Term Loans + Mortgage Payable + Other Long-Term Borrowings − Current Portion of Long-Term Debt
RXRX Long Term Debt Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +93.8% | +16.3% |
| 3 y3 years | +765.1% | +16.3% |
| 5 y5 years | +452.1% | +16.3% |
RXRX Long Term Debt Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +765.1% | at high | +765.1% |
| 5 y | 5-year | at high | +765.1% | at high | +1996.0% |
| alltime | all time | at high | +765.1% | at high | +1996.0% |
Recursion Pharmaceuticals Long Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $86.27 M(+93.8%) | $86.27 M(+16.3%) |
| Sep 2024 | - | $74.17 M(+1.4%) |
| Jun 2024 | - | $73.16 M(+63.1%) |
| Mar 2024 | - | $44.86 M(+0.8%) |
| Dec 2023 | $44.52 M(-1.0%) | $44.52 M(-2.0%) |
| Sep 2023 | - | $45.43 M(-3.4%) |
| Jun 2023 | - | $47.01 M(-2.0%) |
| Mar 2023 | - | $47.95 M(+6.7%) |
| Dec 2022 | $44.96 M | $44.96 M(-3.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $46.55 M(-3.7%) |
| Jun 2022 | - | $48.35 M(+0.9%) |
| Mar 2022 | - | $47.93 M(+380.6%) |
| Dec 2021 | $9.97 M(-29.4%) | $9.97 M(+142.3%) |
| Sep 2021 | - | $4.12 M(-65.3%) |
| Jun 2021 | - | $11.85 M(-8.1%) |
| Mar 2021 | - | $12.89 M(-8.7%) |
| Dec 2020 | $14.12 M(-9.6%) | - |
| Dec 2020 | - | $14.12 M |
| Dec 2019 | $15.63 M | - |
FAQ
- What is Recursion Pharmaceuticals annual long term debt?
- What is the all time high annual long term debt for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual long term debt year-on-year change?
- What is Recursion Pharmaceuticals quarterly long term debt?
- What is the all time high quarterly long term debt for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly long term debt year-on-year change?
What is Recursion Pharmaceuticals annual long term debt?
The current annual long term debt of RXRX is $86.27 M
What is the all time high annual long term debt for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual long term debt is $86.27 M
What is Recursion Pharmaceuticals annual long term debt year-on-year change?
Over the past year, RXRX annual long term debt has changed by +$41.76 M (+93.80%)
What is Recursion Pharmaceuticals quarterly long term debt?
The current quarterly long term debt of RXRX is $86.27 M
What is the all time high quarterly long term debt for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly long term debt is $86.27 M
What is Recursion Pharmaceuticals quarterly long term debt year-on-year change?
Over the past year, RXRX quarterly long term debt has changed by +$12.10 M (+16.31%)